Your browser doesn't support javascript.
loading
Phase III, randomised, double-blind, placebo-controlled study of the ß3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder.
Yamaguchi, Osamu; Marui, Eiji; Kakizaki, Hidehiro; Homma, Yukio; Igawa, Yasuhiko; Takeda, Masayuki; Nishizawa, Osamu; Gotoh, Momokazu; Yoshida, Masaki; Yokoyama, Osamu; Seki, Narihito; Ikeda, Yasushi; Ohkawa, Sumito.
Affiliation
  • Yamaguchi O; Division of Bioengineering and LUTD Research, School of Engineering, Nihon University, Koriyama, Japan.
BJU Int ; 113(6): 951-60, 2014 Jun.
Article in En | MEDLINE | ID: mdl-24471907
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thiazoles / Urinary Bladder, Overactive / Adrenergic beta-3 Receptor Agonists / Acetanilides Type of study: Clinical_trials Aspects: Patient_preference Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: BJU Int Journal subject: UROLOGIA Year: 2014 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Thiazoles / Urinary Bladder, Overactive / Adrenergic beta-3 Receptor Agonists / Acetanilides Type of study: Clinical_trials Aspects: Patient_preference Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: BJU Int Journal subject: UROLOGIA Year: 2014 Document type: Article Affiliation country: